Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study

201886 citationsJournal Articlehybrid Open Access

Authors

Fernando Rivera · Marqués de Valdecilla University Hospital

Manuel Benavides · Hospital Clínico Universitario Virgen de la Victoria

Javier Gállego · Hospital General Universitario de Elche

Carmen Guillén‐Ponce · Hospital Universitario Ramón y Cajal

José A. López-Martín · Research Institute Hospital 12 de Octubre

Marc Küng · Réseau Fribourgeois de Santé Mentale

Abstract

The PANOVA trial demonstrated that the combination of TTFields and systemic chemotherapy is safe and tolerable in patients with advanced PDAC. Based on the safety and preliminary efficacy results of this phase 2 study, a randomized phase 3 study (PANOVA-3) is underway.

Topics & Keywords

Glioma Diagnosis and Treatment Pancreatic and Hepatic Oncology Research Brain Metastases and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Pancreatology

Volume 19, Issue 1, pp. 64-72

DOI: 10.1016/j.pan.2018.10.004

Field-Weighted Citation Impact: 3.78